The biosimilar of infliximab, CT-P13, demonstrated equivalency in safety and efficacy for the treatment of Crohn’s disease, according to data published in Annals of Internal Medicine.
“CT-P13 is a biosimilar of the reference product infliximab, with demonstrated efficacy and safety for some inflammatory arthritides,” Antoine Meyer, MD, from Hôpital Bicêtre, Le Kremlin-Bicêtre, France, and colleagues wrote. “It was approved for the treatment of Crohn’s disease on that basis, without specific studies examining its effects in Crohn’s disease.”

Source link